Oral Recombinant Methioninase Combined with Caffeine and Doxorubicin Induced Regression of a Doxorubicin-resistant Synovial Sarcoma in a PDOX Mouse Model
Higuchi T, Kawaguchi K, Miyake K, Han Q, Tan Y, Oshiro H, Sugisawa N, Zhang Z, Razmjooei S, Yamamoto N, Hayashi K, Kimura H, Miwa S, Igarashi K, Chawla SP, Singh AS, Eilber FC, Singh SR, Tsuchiya H, Hoffman RM
Anticancer research · 39 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Estudio en animales (clasificado por nuestro filtro de IA)
- Estudiado en
- Animales
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2018-10-01 · Anticancer Res · vol. 38 · número 10 · págs. 5639–5644
- Editorial
- International Institute of Anticancer Research (IIAR) Conferences 1997. Athens, Greece. Abstracts
- Citado
- 75 citas · más que el 98% de estudios similares · 6.2× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 26 trabajos
- Acceso
- Lectura gratuita
- Áreas de investigación
- Cancer Research and Treatments · Virus-based gene therapy research · Photodynamic Therapy Research Studies
- Palabras clave
- Doxorubicin, Recombinant DNA, Synovial sarcoma, Sarcoma, Caffeine, Cancer research, Pharmacology, Biology, Medicine, Chemotherapy, Chemistry, Internal medicine, Biochemistry, Pathology, Gene
- MeSH
- tumor cells, cultured, animals, humans, mice, mice, nude, sarcoma, synovial, caffeine, doxorubicin, carbon-sulfur lyases, recombinant proteins, central nervous system stimulants, antibiotics, antineoplastic, combined modality therapy, administration, oral, xenograft model antitumor assays, drug resistance, neoplasm, middle aged, male
20 autores
- Takashi Higuchi🇯🇵🇺🇸Kanazawa University; University of California San Diego; AntiCancer (United States)
- Kei Kawaguchi🇺🇸University of California San Diego; AntiCancer (United States)
- Kentaro Miyake🇺🇸University of California San Diego; AntiCancer (United States)
- Qinghong Han🇺🇸AntiCancer (United States)
- Yuying Tan🇺🇸AntiCancer (United States)
- Hiromichi Oshiro🇺🇸University of California San Diego; AntiCancer (United States)
- Norihiko Sugisawa🇺🇸University of California San Diego; AntiCancer (United States)
- Zhiying Zhang🇺🇸University of California San Diego; AntiCancer (United States)
- Sahar Razmjooei🇺🇸AntiCancer (United States)
- Norio Yamamoto🇯🇵Kanazawa University
- Katsuhiro Hayashi🇯🇵Kanazawa University
- Hiroaki Kimura🇯🇵Kanazawa University
- Shinji Miwa🇯🇵Kanazawa University
- Kentaro Igarashi🇯🇵Kanazawa University
- Sant P. Chawla🇺🇸Sarcoma Oncology Center
- Arun S. Singh🇺🇸University of California San Diego
- Frederick C. Eilber🇺🇸University of California San Diego
- Shree Ram Singh🇺🇸Frederick National Laboratory for Cancer Research
- Hiroyuki Tsuchiya🇯🇵Kanazawa University
- Robert M. Hoffman🇺🇸University of California San Diego; AntiCancer (United States)
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background/aim
Synovial sarcoma (SS) is a recalcitrant neoplasm with low chemosensitivity. We recently reported that recombinant methioninase (rMETase) inhibited SS growth in a patient-derived orthotopic xenograft (PDOX) mouse model and was more effective when administered in combination with the first-line drug doxorubicin (DOX). Caffeine enhances the efficacy of anticancer drugs by overcoming drug-induced cell-cycle arrest and increasing subsequent apoptosis. Here, we determined the efficacy of oral recombinant methioninase (o-rMETase) in combined with caffeine on an SS-PDOX model.
Materials and methods
Mice bearing SS-PDOX tumors were randomized into four treatment groups of six: Untreated control; o-rMETase alone; o-rMETase with caffeine; DOX plus o-rMETase with caffeine. Tumor size and body weight were measured during the treatment and plasma L-methionine (MET) levels were measured at the end of treatment.
Results
All treatments significantly inhibited SS-PDOX tumor growth. Combining caffeine with o-rMETase was more effective than o-rMETase alone. DOX combined with o-rMETase and caffeine led to regression of SS-PDOX. Plasma MET levels were reduced with o-rMETase treatment.
Conclusion
These results suggest that combining o-rMETase and caffeine along with first-line chemotherapy can be highly effective for SS and has clinical potential for this recalcitrant disease.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.